← Eichor
Condition: Unresectable Urothelial Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Unresectable Urothelial Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Phase 1 · 1 location(s) · Emory University · NCT04878029Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
Phase N/A · 1 location(s) · Dana-Farber Cancer Institute · NCT06138561A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 · 17 location(s) · Nurix Therapeutics, Inc. · NCT05107674A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Phase 2 · 221 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT04879329Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma
Phase 2 · 1 location(s) · Fox Chase Cancer Center · NCT07221942Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Local
Phase 2 · 1 location(s) · Xiujuan Qu · NCT07506057Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Phase 1 · 122 location(s) · Exelixis · NCT05176483A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Phase 1/Phase 2 · 7 location(s) · Astellas Pharma Global Development, Inc. · NCT07287995Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Loc
Phase 1/Phase 2 · 18 location(s) · Aulos Bioscience, Inc. · NCT05267626A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerabili
Phase 1/Phase 2 · 10 location(s) · ITM Oncologics GmbH · NCT05706129A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
Phase 3 · 2 location(s) · RemeGen Co., Ltd. · NCT05302284Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381A Phase 2 Clinical Study of ABSK061 and ABSK043
Phase 2 · 21 location(s) · Abbisko Therapeutics Co, Ltd · NCT06632262Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Imm
Phase 1 · 11 location(s) · National Cancer Institute (NCI) · NCT06439836Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access an
Phase 2 · 1 location(s) · Mayo Clinic · NCT06265285A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatme
Phase 3 · 159 location(s) · National Cancer Institute (NCI) · NCT06524544
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.